COVID-19 Drug Treatment* Chromatography, High Pressure Liquid / methods Chromatography
Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19
-Y
Pharmacokinetics and bioequivalence study of hydroxychloroquine sulfate tablets in Chinese healthy volunteers by
In fact, the FDA has revoked emergency use authorization for HCQ in COVID-19 patients based on these dangers and because it does not help people recover faster
Hydroxychloroquine (HCQ) has shown efficacy against coronavirus disease 2019 (COVID-19) in some but not all studies
Usual SOC plus HCQ sulfate tablets at 200 mg (containing 155-mg base equivalent) in a loading dose of 4 tablets at baseline and at 6 h, and followed by 2 tablets starting at 12 h after the initial dose and then bid for the next 9 days or until discharge, whichever occurred earlier (total dose: 9200 mg) Treating COVID-19
2, 2020, the Centers for Disease Control and Prevention has reported more than 9
Theoretically, use of interleukin 6 (IL-6) inhibitors as immunomodulators and other immunomodulatory agents may be promising in severe cases, but supportive care currently remains one of the cornerstones of therapy for COVID-19
This pathogen was previously unknown and was named as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) []